Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vernonia amygdalina leaf extract
- Development stage
- Unknown
- Lead developer
- National Institutes of Pharmaceutical R&D
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Topical
01
Overview
Vernonia amygdalina leaf extract, commonly known as bitter leaf extract, is a natural product and herbal extract derived from the leaves of the African shrub *Vernonia amygdalina*. It has a long history of use in traditional African medicine for treating malaria, gastrointestinal disorders, fever, and diabetes. Standardized formulations, such as Roveda (also spelled Rofeda) capsules, have been developed by Benson Idahosa University and commercialized by May & Baker Nigeria, while Neimeth International Pharmaceuticals has also pursued its development. Preclinical and clinical studies have demonstrated its potential antidiabetic, antiplasmodial, hepatoprotective, and antimicrobial properties, with mechanisms of action involving antioxidant activity, insulin sensitization, and alpha-glucosidase and alpha-amylase inhibition.
- Brand names
- RofedaRoveda
- Other names
- Chusar-dokiCongo BololoEtidotEwuroOnubuOriwoShuwakaVernonia amygdalina extractVernonia amygdalina leaf extractbitter leaf extract
02
Targets
AMY (Pancreatic alpha-amylase)Sucrase-Isomaltase
Beyond the preview
Go deeper on Vernonia amygdalina leaf extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vernonia amygdalina leaf extract.